Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | CuttingEdgeInfo Reports | Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Mergers and Acquisitions (PH133)

Ensure merger and acquisition success - at any point in the M&A process

Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape.

The past year has been marked by heightened M&A activity among companies of all sizes. Small companies are increasingly investing in large-molecule products that are expensive to produce and test in clinical trials - but in this tough economic climate, they face diminishing capital and the threat of closing. To continue their work on time-sensitive compounds, they are exploring the possibility of a company sale. On the other hand, for those companies with cash, this situation presents an opportunity to acquire attractive compounds and technology platforms at a discount.

Timelines, rankings, strategies, and deal profiles will allow you to maximize the benefits and growth opportunities of a deal:

Understand the M&A environment

Learn what is driving the acquisition strategies of top companies - and how other organizations are seeking suitors for their own sales.

Build a competitive deal-making process

* Target the right deals with an M&A task force

* Implement a timeline that works for both sides

* Track different types of financing across deals brokered by companies of different sizes

Complete the integration as soon as possible -- and boost productivity

* Build an integration timeline

* Clarify roles and responsibilities in the new organization

* Reduce the impact of attrition

Learn from the recent past

We've vetted the top 75 deals of 2009 to determine purchasing trends, including:

* Price/pipeline ratios

* Financing options

* Deal motivators

Look into the future of M&A

Gather perspectives and predictions on future deals from the managers who execute them.

Compare your deal to others

* Use the deal profiles to compare metrics for 19 different deals

* Explore deal size, functional involvement in deal-making, timelines, challenges and employee retention

Companies featured in this report

* Advanced Refractive Technologies

* Anavex

* ApotheCom

* AstraZeneca

* Bristol-Myers Squibb

* Centocor

* Ethypharm

* Galderma

* IBA

* Lyotropic Therapeutics

* Metabolex

* Novagali Pharma

* Novartis

* Novex Pharmaceuticals

* NPS Pharmaceuticals

* OCO Biomedical

* Orion Corporation

* Otsuka Pharmaceutical Co.

* Penwest

* Schering-Plough

* Strategent Life Sciences

* Talima Therapeutics

* UCB

* Vivabiocell

Published 2009

175 Pages

400+ Metrics

45+ Companies
Metrics
Price: $7,695.00 / €5,096.40

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions